ChemotherapyFDA-approvedFirst-line
Pemetrexed
How it works
Inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, disrupting DNA synthesis and cell division.
Cancer types
Lung Cancer— All patients
Efficacy
Studies show that pemetrexed plus platinum chemotherapy improves overall survival compared to platinum chemotherapy alone in patients with non-squamous non-small cell lung cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Rare Skin Reaction Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Methoxyamine with Cisplatin and Pemetrexed in Advanced Cancer Patients | Lung Cancer | phase-1 | — | Source → |
| Traditional Chinese Medicine May Help Reduce Chemotherapy Side Effects in Lung Cancer Patients | Lung Cancer | phase-3 | The incidence of neurotoxicity was 29.1% in the treatment group, significantly lower than 51.8% in the control group. | Source → |
| Pemetrexed Side Effects Study Identifies New Safety Signals | Lung Cancer | observational | — | Source → |
| Taxane Chemotherapy May Be More Effective Than Pemetrexed in Lung Cancer | Lung Cancer | observational | Taxanes showed numerically longer progression-free survival (PFS; median 8.8 vs 7.9 months) and overall survival (OS; 18.8 vs 15.9 months) versus pemetrexed. | Source → |
| Combining Medications Improves Lung Cancer Treatment for Some Patients | Lung Cancer | phase-3 | Combination therapy significantly prolonged median progression-free survival compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). | Source → |
| New Treatment for Lung Cancer | Lung Cancer | observational | — | Source → |
| New Treatment Combination Shows Promise for Lung Cancer Patient | Lung Cancer | observational | The treatment successfully prolonged the patient's survival by 3 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.